Current opinion in infectious diseases · 2025
Eravacycline: from clinical trials to its potential place in everyday therapy.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vena Antonio, Castaldo Nadia, Giacobbe Daniele Roberto, Taramasso Lucia, Fantin Alberto, Bassetti Matteo
Аннотация
PURPOSE OF REVIEW: The ongoing emergence of multidrug-resistant (MDR) pathogens represents a major challenge in clinical practice, highlighting the need of novel antimicrobial agents. Eravacycline, a synthetic fluorocycline, has shown potent in-vitro activity against a broad spectrum of Gram-positive, Gram-negative, and anaerobic pathogens. This review aims to summarize the antimicrobial profile, pharmacokinetics, clinical efficacy, and safety of eravacyclineand and explores its potential applications in routine clinical practice.
RECENT FINDINGS: Eravacycline has been approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of complicated intra-abdominal infections (cIAIs). Phase III clinical trials (IGNITE 1 and IGNITE 4) have demonstrated its noninferiority to carbapenems for cIAIs, with a favorable safety profile. Real-world evidence indicates that eravacycline is increasingly used for infections beyond its approved indications, including pneumonia, bloodstream infections, and skin and soft tissue infections. In-vitro studies indicate strong activity against Enterobacterales, carbapenem-resistant Enterobacterales and Acinetobacter baumannii, as well as vancomycin-resistant Enterococcus, supporting its potential role for difficult-to-treat infections.
SUMMARY: While clinical data remain limited, eravacycline appears promising for the treatment of infections caused by MDR pathogens, particularly in patients with limited therapeutic options or intolerance to β-lactams. As resistance mechanisms continue to evolve, the role of eravacycline in real-world clinical practice may extend beyond its current indications, warranting further research to define its optimal therapeutic applications.
RECENT FINDINGS: Eravacycline has been approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of complicated intra-abdominal infections (cIAIs). Phase III clinical trials (IGNITE 1 and IGNITE 4) have demonstrated its noninferiority to carbapenems for cIAIs, with a favorable safety profile. Real-world evidence indicates that eravacycline is increasingly used for infections beyond its approved indications, including pneumonia, bloodstream infections, and skin and soft tissue infections. In-vitro studies indicate strong activity against Enterobacterales, carbapenem-resistant Enterobacterales and Acinetobacter baumannii, as well as vancomycin-resistant Enterococcus, supporting its potential role for difficult-to-treat infections.
SUMMARY: While clinical data remain limited, eravacycline appears promising for the treatment of infections caused by MDR pathogens, particularly in patients with limited therapeutic options or intolerance to β-lactams. As resistance mechanisms continue to evolve, the role of eravacycline in real-world clinical practice may extend beyond its current indications, warranting further research to define its optimal therapeutic applications.